Sunday, November 22, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· January 21, 2026

Johnson & Johnson reports Q4 and Full-Year 2025 results

View original at finance.yahoo.com
“2025 Full-Year reported sales growth of 6.0% to $94.2 Billion”
Verbatim excerpt from the source · Yahoo Finance · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2026 adjusted operational EPS guidance of $11.28-$11.48 with midpoint of $11.38 representing 5.5% growth

    80% confidence
  • 2026 adjusted EPS guidance of $11.43-$11.63 with midpoint of $11.53 representing 6.9% growth

    80% confidence
  • TREMFYA is the only IL-23 inhibitor proven to inhibit structural joint damage in active psoriatic arthritis

    80% confidence
  • INLEXZO achieved 74% disease-free survival at one year in BCG-unresponsive high-risk papillary-only NMIBC

    80% confidence
  • DARZALEX FASPRO is the first/only FDA-approved treatment for high-risk smoldering multiple myeloma

    80% confidence
  • 2026 adjusted operational sales growth guidance of 5.4%-6.4% with midpoint of 5.9%

    80% confidence
  • RYBREVANT FASPRO + LAZCLUZE has the shortest administration time for first-line combination regimen

    80% confidence
  • 2026 operational sales guidance of $99.5B-$100.5B with midpoint of $100.0B representing 6.2% growth

    80% confidence
  • TECVAYLI + DARZALEX FASPRO demonstrated superior PFS and OS vs. standard of care in second-line multiple myeloma

    80% confidence
  • Nipocalimab is the first/only investigational FcRn blocker showing potential to reduce SLE activity in Phase 2

    80% confidence
  • AKEEGA demonstrates 54% reduction in disease progression in BRCA2-mutated metastatic castration-sensitive prostate cancer

    80% confidence
  • 2026 reported sales guidance of $100.0B-$101.0B with midpoint of $100.5B representing 6.7% growth

    80% confidence
  • Subcutaneous amivantamab achieved 45% overall response rate with 7.2-month median duration in recurrent/metastatic head and neck cancer

    80% confidence

Cited in these Via News reports